CH676715A5 - - Google Patents

Download PDF

Info

Publication number
CH676715A5
CH676715A5 CH3921/88A CH392188A CH676715A5 CH 676715 A5 CH676715 A5 CH 676715A5 CH 3921/88 A CH3921/88 A CH 3921/88A CH 392188 A CH392188 A CH 392188A CH 676715 A5 CH676715 A5 CH 676715A5
Authority
CH
Switzerland
Prior art keywords
group
mpl
acid
monophosphoryl lipid
hydrogen
Prior art date
Application number
CH3921/88A
Other languages
German (de)
English (en)
Inventor
Kent R Myers
Edgar E Ribi
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of CH676715A5 publication Critical patent/CH676715A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06Fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/06Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CH3921/88A 1987-10-22 1988-10-21 CH676715A5 (Sortimente)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/112,742 US4987237A (en) 1983-08-26 1987-10-22 Derivatives of monophosphoryl lipid A

Publications (1)

Publication Number Publication Date
CH676715A5 true CH676715A5 (Sortimente) 1991-02-28

Family

ID=22345625

Family Applications (1)

Application Number Title Priority Date Filing Date
CH3921/88A CH676715A5 (Sortimente) 1987-10-22 1988-10-21

Country Status (10)

Country Link
US (1) US4987237A (Sortimente)
JP (1) JPH075623B2 (Sortimente)
BE (1) BE1003250A5 (Sortimente)
CA (1) CA1308711C (Sortimente)
CH (1) CH676715A5 (Sortimente)
DE (1) DE3836006C2 (Sortimente)
FR (1) FR2622192A1 (Sortimente)
GB (1) GB2211502B (Sortimente)
IT (1) IT1230592B (Sortimente)
NL (1) NL8802595A (Sortimente)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
EP0482068A1 (en) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5498708A (en) * 1989-07-18 1996-03-12 Montefiore Medical Center Method of synthesizing polyesters
EP0482206A4 (en) * 1990-04-12 1992-08-19 Japan Tobacco Inc. 4,6-o-hydroxyphosphorylglucosamine derivative
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5164375A (en) * 1991-09-27 1992-11-17 Merck & Company, Inc. Antifungal agent
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6290971B1 (en) * 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
HU230847B1 (en) 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
ES2336080T3 (es) * 2002-02-04 2010-04-08 Corixa Corporation Nuevos compuestos inmunoefectores.
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
AU2003213640A1 (en) * 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
PL220778B1 (pl) 2002-07-08 2016-01-29 Corixa Corp Sposoby wytwarzania 4-fosforanu aminoalkiloglukozaminidu oraz związki pośrednie
EP2940028B8 (en) 2003-01-06 2017-09-27 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DK1449535T3 (da) * 2003-02-18 2006-09-11 Clinique La Prairie Res Sa Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2468300T1 (en) 2006-09-26 2018-03-30 Infectios Disease Research Institute A vaccine composition comprising a synthetic adjuvant
KR101580660B1 (ko) 2007-08-02 2015-12-28 바이오앤드백스 파마슈티칼즈, 리미티드. 다중체 다중-에피토프 인플루엔자 백신
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US8637053B2 (en) 2007-12-03 2014-01-28 President And Fellows Of Harvard College Chlamydia antigens
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
US9895435B2 (en) 2012-05-16 2018-02-20 Immune Design Corp. Vaccines for HSV-2
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
DK2958935T3 (da) 2013-02-20 2019-09-16 Bergen Teknologioverforing As Vaccine
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのgla単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
AU2018331874B2 (en) 2017-09-13 2022-06-02 Sanofi Pasteur Human cytomegalovirus immunogenic composition
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US20220249644A1 (en) 2018-08-24 2022-08-11 Vestlandets Innovasjonsselskap As (Vis) Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens
CA3155424A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
PL4090363T3 (pl) 2020-01-16 2024-11-25 Janssen Pharmaceuticals, Inc. Mutant fimh, jego kompozycje i jego zastosowanie
KR102746713B1 (ko) 2021-01-12 2024-12-24 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of E. Coli O18 bioconjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0414725Y2 (Sortimente) * 1980-09-30 1992-04-02
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS62129293A (ja) * 1985-11-28 1987-06-11 Toho Yakuhin Kogyo Kk 親水性のリピドa単糖類縁体
JPS62195396A (ja) * 1986-02-20 1987-08-28 Toho Yakuhin Kogyo Kk 親水性及び疎水性の基を置換したりピドa単糖類縁体

Also Published As

Publication number Publication date
GB2211502A (en) 1989-07-05
GB2211502B (en) 1992-02-19
JPH01146891A (ja) 1989-06-08
BE1003250A5 (fr) 1992-02-11
FR2622192B1 (Sortimente) 1994-11-10
JPH075623B2 (ja) 1995-01-25
JPH075623B1 (Sortimente) 1995-01-25
IT8822399A0 (it) 1988-10-21
DE3836006C2 (de) 1996-07-11
US4987237A (en) 1991-01-22
GB8824330D0 (en) 1988-11-23
FR2622192A1 (fr) 1989-04-28
CA1308711C (en) 1992-10-13
NL8802595A (nl) 1989-05-16
IT1230592B (it) 1991-10-28
DE3836006A1 (de) 1989-05-03

Similar Documents

Publication Publication Date Title
CH676715A5 (Sortimente)
KR860000274B1 (ko) 갱글리오사이드의 분자내 에스테르 유도체의 제조방법
DE2655500C2 (Sortimente)
EP0519327B1 (de) N-Acyl-S-(2-hydroxyalkyl)-cysteine, deren Herstellung sowie deren Verwendung als Zwischenprodukte zur Herstellung von synthetischen Immunadjuvantien und synthetischen Impfstoffen
DE69103255T2 (de) Säureempfindliche Linkermoleküle.
DE60023748T2 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DD160417A5 (de) Verfahren zur herstellung von n-(vinblastin-23-oyl)-aminosaeurederivate
DE4115468A1 (de) Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
DE3887820T2 (de) Antibiotika, Benanomicine A und B und Dexylosylbenanomicin B, ihre Herstellung und Verwendung.
US4304726A (en) Process for the preparation of cholesterol derivatives
DE69131662T2 (de) Lipopeptide, T-cytotoxische Lymphocyte aktivierend, und deren Verwendung als Vakzine
DE69033257T2 (de) Zytotoxische zyklische Depsipeptide des Manteltierchen Trididemnum Solidum
EP0658585B1 (de) Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
DE3044740A1 (de) Nucleosidderivate, ihre herstellung und pharmazeutische mittel
EP0060999B1 (de) Galactopyranoside Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antigene oder Immunadsorbentien
DE2557145C3 (de) Tyrosinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE69019217T2 (de) Perylenquinon (UCN-1028D)-Derivate.
EP0442372A1 (de) Verbesserte markierte Haptene, Verfahren zu deren Herstellung sowie Verwendung dieser markierten Haptene in Immunoassays
US4225525A (en) Vitamin D3 metabolite derivatives
EP0267179A2 (de) Neue Cystinverbindungen, ihre Herstellung und Verwendung
WO2004083223A1 (de) Proteinbindende derivate von platinkomplexen mit cyclobutan-1,1-dicarboxylatliganden
DE68913936T2 (de) Retro-Inverso-Thrymopentin-Analoge, Verfahren zu deren Herstellung und deren Verwendung für die Zubereitung von pharmazeutischen Zusammensetzungen.
DE69017771T2 (de) Thymopentin-Analoge mit allen umgekehrten Verbindungen, Verfahren zur deren Herstellung und deren Verwendung zur Herstellung von pharmazeutischen Zusammensetzungen.
DD262998A5 (de) Verfahren zur herstellung eines konjugates von einem vinca-alkaloid mit einem protein
CH628323A5 (de) Verfahren zur herstellung von cholecystokinin-pancreozymin-octapeptidamid-sulfatester.

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: RIBI IMMUNOCHEM RESEARCH, INC.

Free format text: RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US) -TRANSFERTO- RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US)

PL Patent ceased